Obesity最新文献

{"title":"Dynamic Network Reconfiguration of Brain Function During Exposure to Aversive Stimuli","authors":"Zhoukang Wu,&nbsp;Min Wang,&nbsp;Lei Guo,&nbsp;Hui Zheng,&nbsp;Liangjiecheng Huang,&nbsp;Ting Xu,&nbsp;Qing Li,&nbsp;Jianzhong Di,&nbsp;Xiaodong Han","doi":"10.1002/oby.70226","DOIUrl":"10.1002/oby.70226","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Obesity, a critical public health challenge, involves dysregulated food stimuli responses central to its pathophysiology. Aversion to harmful food is protective, but dynamic brain network reorganization during aversion processing in obesity and its clinical implications remain inadequately understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Brain activity was recorded from 30 participants with obesity and 35 healthy participants during exposure to spoiled food videos in an MRI scanner. We applied dynamic network analysis to assess obesity-related alterations in neural circuits and their links to eating disorders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The group with obesity showed significantly lower integration between the visual (VN), dorsal attention (DAN), and subcortical (SUB) networks than the healthy control group while viewing spoiled food videos. Critically, this DAN-SUB integration correlated positively with body image distress and negatively with craving ratings, and it moderated the predictive link between cognitive impulsivity and eating disorders. Granger causality analysis confirmed a dominant indirect pathway with stronger effective connectivity, showing differential spatial associations with neurotransmitter receptors (α4β2, mGluR5, NMDA, and CB1).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study reveals VN-DAN-SUB dynamic interactions in aversion processing, emphasizing the indirect pathway's key role. Inefficient VN-DAN-SUB coordination in obesity may impair aversive food stimuli regulation, supporting the emotion regulation deficit hypothesis and offering a neurobiological basis for future interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 7","pages":"1446-1456"},"PeriodicalIF":4.9,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70226","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148255299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twenty-Four Month Outcomes From a Real-World Telehealth Obesity Treatment Clinic Using Obesity Medications","authors":"Kathleen R. Ruddiman,&nbsp;Young-Rock Hong,&nbsp;Jamy Ard,&nbsp;Rebecca Jones,&nbsp;Adam Medcalf,&nbsp;Gary D. Foster,&nbsp;Jamil Alkhaddo,&nbsp;Michelle Cardel","doi":"10.1002/oby.70156","DOIUrl":"10.1002/oby.70156","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Antiobesity medications (AOMs) are indicated for long-term use; however, evidence of their real-world long-term efficacy is limited. This study describes clinical outcomes from 18- and 24-month use of AOMs in a telemedicine weight management clinic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective observational study analyzed data from adult participants who utilized AOMs at a telemedicine weight management clinic between January 2022 and December 2024. Weight change analyses were conducted for those maintaining AOM use for ≥ 18 months (<i>n</i> = 11,675) and ≥ 24 months (<i>n</i> = 4317). Weight outcomes were assessed across all AOMs and stratified based on classification of AOMs utilized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Across all AOMs, average total body weight reduction of −18.53% (95% CI: −18.74%, −18.32%) was observed at 18 months and −20.27% (95% CI: −20.63%, −19.92%) seen at 24 months. For those taking long-acting AOMs, outcomes trended toward greater weight loss in comparison with participants using oral AOMs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This real-world analysis found 18- and 24-month weight losses comparable to those demonstrated in clinical trials, supporting the long-term efficacy of AOMs provided by a telemedicine weight management clinic. Continued weight loss was demonstrated between 18 and 24 months, suggesting sustained engagement with AOMs and a telemedicine weight management clinic support continued weight loss in the long term.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"134-143"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70156","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural Drivers of Neighborhood Food Access: Implications for Policy Change","authors":"Rebekah J. Walker,&nbsp;Obinna Ekwunife,&nbsp;Jennifer A. Campbell,&nbsp;Sebastian Linde,&nbsp;Leonard E. Egede","doi":"10.1002/oby.70205","DOIUrl":"10.1002/oby.70205","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study investigated structural drivers of neighborhood food access to identify possible pathways at a census tract level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from 9597 census tracts across 201 counties, within 38 states, tested potential pathways including the built environment, criminal justice, education, housing, social cohesion, transportation, wealth, and income/poverty. Historic residential redlining was defined using Home Owners' Loan Corporation residential security maps. Food access was defined using the modified retail food environment index. Direct and indirect relationships were investigated using structural equation modeling (SEM) run in Stata v18, controlling for the population of each census tract. Standardized estimates were used with <i>p</i> &lt; 0.05 considered statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Redlining was directly associated with higher disadvantage across all tested pathways. Higher disadvantage in the built environment (−0.06, <i>p</i> &lt; 0.001), criminal justice (−0.11, <i>p</i> &lt; 0.001), housing (−0.04, <i>p</i> &lt; 0.01), and social cohesion (−0.18, <i>p</i> &lt; 0.001) was associated with lower food access, while higher disadvantage in education was associated with higher food access (0.07, <i>p</i> &lt; 0.001), and transportation, wealth, and income were not significant pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The strongest neighborhood-level drivers were social cohesion, criminal justice, and education. Policies that focus on a holistic approach to the neighborhood environment may be needed to improve access to healthy food options at the neighborhood level.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"144-152"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147701429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prepregnancy GLP-1RA Exposure and Risk of Hypertensive Disorders of Pregnancy Among Women With Obesity and Diabetes","authors":"Dominick J. Lemas,&nbsp;Ruben Zapata,&nbsp;Isaac Loy,&nbsp;Aditya Mahadevan,&nbsp;Tony Wen,&nbsp;Rahma Mkuu,&nbsp;Adetola Louis-Jaques,&nbsp;Jaclyn Hall,&nbsp;Kylie K. Harrall,&nbsp;Larissa Strath,&nbsp;Amy Sheer,&nbsp;Elizabeth Shenkman,&nbsp;Serena Guo,&nbsp;Michelle I. Cardel,&nbsp;Steve Smith","doi":"10.1002/oby.70221","DOIUrl":"10.1002/oby.70221","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are prescribed to women of reproductive age for obesity, type 2 diabetes, obstructive sleep apnea, and more. Data on pregnancy outcomes following prepregnancy exposure remain limited. We evaluated associations between prepregnancy GLP-1RA exposure and maternal and neonatal outcomes among women with preexisting obesity and diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study using electronic health records data. Prepregnancy GLP-1RA exposure was defined by prescription orders within 12 and 24 months prior to delivery. Propensity score matching was performed using maternal age, race and ethnicity, prepregnancy obesity status, diabetes type, chronic hypertension, insurance type, and rurality. Primary outcomes included preeclampsia (PE). Secondary outcomes included cesarean delivery, infant growth, gestational age at delivery, and neonatal intensive care unit length of stay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 31 exposed pregnancies, 29 were matched to unexposed controls. GLP-1RA exposure was associated with higher prevalence of PE (12 months: <i>p</i> = 0.023; 24 months: <i>p</i> = 0.018). Cesarean delivery occurred more frequently among exposed pregnancies (<i>p</i> &lt; 0.05). No differences were observed in neonatal outcomes after matching.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Prepregnancy GLP-1RA exposure was associated with higher prevalence of PE and cesarean delivery in this cohort. Larger studies are needed to confirm these findings and clarify underlying mechanisms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"88-96"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147936735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"G Protein-Coupled Receptor 17 (Gpr17) Enhances Leptin and Insulin Sensitivity in Lean and Obese Mouse Models","authors":"Xun Sun,&nbsp;Connor Mahler,&nbsp;Natalie D. Stull,&nbsp;Ali Nasiri,&nbsp;Baohua Zhou,&nbsp;Varman Samuel,&nbsp;Gerald Shulman,&nbsp;Jonathan N. Flak,&nbsp;Hongxia Ren","doi":"10.1002/oby.70202","DOIUrl":"10.1002/oby.70202","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Obesity, a major driver for diabetes development, is characterized by insulin and leptin resistance. We previously showed that loss of G protein-coupled receptor 17 (Gpr17) in specific hypothalamic neurons and the intestine led to better energy balance and glucose metabolism. Our goal is to test whether general loss of Gpr17 enhances insulin and leptin sensitivity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We generated germline <i>Gpr17</i> knockout mice on both lean (<i>Gpr17</i>\u0000 ^{\u0000 <i>−/−</i>\u0000}) and obese (<i>Gpr17</i>\u0000 ^{\u0000 <i>−/−</i>\u0000}; <i>ob/ob</i>) backgrounds and characterized their metabolic profile.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>\u0000 <i>Gpr17</i>\u0000 ^{\u0000 <i>−/−</i>\u0000} mice exhibited increased energy expenditure and oxygen consumption. Euglycemic-hyperinsulinemic clamp studies showed enhanced insulin sensitivity in <i>Gpr17</i>\u0000 ^{\u0000 <i>−/−</i>\u0000} mice with increased glycogen synthesis and decreased glycolysis. <i>Gpr17</i>\u0000 ^{\u0000 <i>−/−</i>\u0000} <i>ob/ob</i> mice had increased insulin sensitivity with lower baseline serum insulin and higher response to exogenous leptin treatment with more reduction in feeding and increased pStat3 activation in hypothalamic nuclei.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings highlight the inhibitory effect of Gpr17 in leptin and insulin sensitivity, suggesting its potential as a therapeutic target for obesity treatment.</p>\u0000 \u0000 <div>\u0000 \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"77-87"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147936733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States","authors":"Jennifer H. Hwang,&nbsp;Neda Laiteerapong","doi":"10.1002/oby.70144","DOIUrl":"10.1002/oby.70144","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023. The Excess Adiposity criteria incorporated BMI, waist circumference, waist to hip and waist to height ratios, and body fat percentage to identify obesity, which was subclassified as preclinical or clinical based on organ dysfunction and activity limitations. Survey-weighted estimates were calculated to produce nationally representative trends.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>By BMI criteria, obesity prevalence increased from 31% (58.8 million) in 1999–2004 to 43% (101.3 million) in 2021–2023. By Excess Adiposity criteria, prevalence was higher and increasing from 51% (94.7 million) to 61% (143.9 million). The prevalence of clinical obesity is high due to a large number of people meeting criteria for organ dysfunction and/or activity limitations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Using the Excess Adiposity criteria to define obesity classifies nearly three in five US adults as having obesity, revealing substantial clinical, public health, and policy implications. The new criteria improve identification of individuals at risk but will require further strategies to achieve equitable, effective, and sustainable obesity prevention and treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"29-42"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147273570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide","authors":"Sarah R. Barenbaum,&nbsp;Ariel Gonzalez,&nbsp;Zoe Verzani,&nbsp;Alice S. Zhao,&nbsp;Alpana P. Shukla","doi":"10.1002/oby.70179","DOIUrl":"10.1002/oby.70179","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study compared weight-loss outcomes in patients prescribed tirzepatide by weight-loss status and assessed results among patients transitioning from semaglutide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study analyzed 6-month weight-loss outcomes in adults treated with tirzepatide between May 2022 and January 2023. Patients were classified as weight-reduced if they had lost ≥ 10% total body weight (TBW) before starting tirzepatide. Among those who switched from therapeutic semaglutide (≥ 1.7 mg weekly for ≥ 1 month), reasons for switching were categorized as non-response (&lt; 5% weight loss after ≥ 3 months), plateau (≥ 5% loss followed by weight stabilization), or other.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 941 charts, 293 (31.1%) met inclusion criteria (65% female; mean age 52 years; mean BMI 36.15 kg/m²). Weight-reduced patients (<i>n</i> = 133) lost 7.2% TBW versus 10.3% in non-weight-reduced patients (<i>n</i> = 160; <i>p</i> &lt; 0.001). When analyses were stratified by type 2 diabetes (T2D) status, this difference remained significant among patients without T2D. Sixty-one patients switched from semaglutide due to non-response or plateau and lost 5.3% TBW. Those switching at a plateau (<i>n</i> = 28) lost 8.1% versus 2.9% for non-responders (<i>n</i> = 33; <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Tirzepatide produced meaningful weight loss across groups but outcomes varied based on weight-reduction status, T2D status, and prior response to semaglutide.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"97-101"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147577278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ObesityWeek® 2025—Reflecting on an Exciting Time in Obesity Research and Treatment","authors":"Susan Z. Yanovski,&nbsp;John Thyfault","doi":"10.1002/oby.70219","DOIUrl":"10.1002/oby.70219","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"7-8"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148059192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Adolescent and Young Adult Obesity Medication Dispensing: A Retrospective Linked EHR-Pharmacy Cohort, 2020–2025","authors":"Isa Granados,&nbsp;Kristen Wolfgang,&nbsp;Kamyar Arasteh,&nbsp;Karthik Viswanathan,&nbsp;Madeleine Snyder,&nbsp;H. Timothy Bunnell,&nbsp;Thao-Ly T. Phan","doi":"10.1002/oby.70128","DOIUrl":"10.1002/oby.70128","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to describe real-world obesity medication (OM) prescribing and dispensing among adolescents and young adults (AYAs) and examine factors associated with dispensing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort linked Nemours Children's Health electronic health record (EHR) to Surescripts dispensing (2020–2025). AYAs aged 12–20 with prescriptions for liraglutide, semaglutide, phentermine, phentermine–topiramate, or tirzepatide were included; youth with diabetes were excluded. Primary outcome was ever dispensed. Multilevel logistic regression assessed the odds of dispensing by race and ethnicity, Child Opportunity Index (COI), health insurance, prescription (Rx) coverage, drug, and prescription year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 1194 AYAs with ≥ 1 OM prescription, 56.7% received ≥ 1 fill. Versus semaglutide, dispensing odds were higher for liraglutide (OR 2.40), phentermine (OR 3.32), and phentermine–topiramate (OR 2.16) and lower for tirzepatide (OR 0.45; all <i>p</i> ≤ 0.003). Hispanic AYAs had lower odds than non-Hispanic White peers (OR 0.61; <i>p</i> ≤ 0.001). Public (OR 1.31) and mixed insurance (OR 1.63) and Rx coverage (OR 2.00; all <i>p</i> ≤ 0.05) were associated with higher odds. Despite increased rates of prescribing each year, rates of dispensing declined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Nearly half of AYA OM prescriptions were never dispensed. Barriers to initiation persist and inequities affect Hispanic youth. Addressing insurance/Rx coverage constraints may improve equitable access.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"102-111"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models","authors":"François Briand,&nbsp;Camille Le Cudennec,&nbsp;Estelle Grasset,&nbsp;Natalia Breyner,&nbsp;Claire Bigot,&nbsp;Pierre Dillard,&nbsp;Thierry Sulpice","doi":"10.1002/oby.70155","DOIUrl":"10.1002/oby.70155","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective/Methods</h3>\u0000 \u0000 <p>Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In mice, retatrutide strongly reduced body weight by 31% (<i>p</i> &lt; 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly. Retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content. In hamsters, retatrutide altered food preference with increased chow diet intake and decreased high fat/cholesterol diet and 10% fructose water intake. The significant weight loss was associated with a reduction in fat and lean mass, but the lean mass was not different after 5 weeks of treatment with no change in mineral bone density. Retatrutide significantly reduced HOMA-IR, plasma triglycerides, and LDL-cholesterol levels. Although retatrutide did not reduce histopathological scoring, there was a 50% reduction in hepatic triglyceride content (<i>p</i> &lt; 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Retatrutide demonstrates multiple metabolic benefits in both mouse and hamster models. Our preclinical setting will help to assess the efficacy of novel therapies targeting obesity and MASH.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"43-53"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70155","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}